Literature DB >> 14665560

Local anaesthetic sensitivities of cloned HERG channels from human heart: comparison with HERG/MiRP1 and HERG/MiRP1 T8A.

P Friederich1, A Solth, S Schillemeit, D Isbrandt.   

Abstract

BACKGROUND: Myocardial potassium channels are complexes formed by different subunits. The subunit composition may influence the cardiotoxic action of local anaesthetics. The effects of amide local anaesthetics on HERG channels co-expressed with the putative subunit MiRP1 have not been established. It is also unclear if the common polymorphism MiRP1(T8A) that predisposes individuals to drug-induced cardiac arrhythmia increases local-anaesthetic sensitivity of HERG/MiRP1 channels. This may suggest the presence of genetic risk factors for local-anaesthetic-induced cardiac arrhythmia.
METHODS: Whole-cell patch-clamp recordings and site-directed mutagenesis were combined to compare local anaesthetic sensitivities of cloned and mutated human potassium channel subunits. The ion channels were activated by a protocol that approximated ventricular action potentials.
RESULTS: The amide local anaesthetics bupivacaine, levobupivacaine and ropivacaine inhibited HERG channels at toxicologically relevant concentrations, with IC(50) values of 20 (SEM 2) micro M (n=29), 10 (1) micro M (n=40) and 20 (2) micro M (n=49), respectively. Hill coefficients were close to unity. There were no indications of qualitative differences in channel inhibition between the three anaesthetics. The putative subunit MiRP1 did not alter local anaesthetic sensitivity of HERG channels. The common single nucleotide polymorphism producing MiRP1(T8A) did not increase local anaesthetic sensitivity of HERG/MiRP1 channels.
CONCLUSIONS: Amide local anaesthetics target HERG and HERG/MiRP1 channels with identical potency. The effects on these ion currents may significantly contribute to local-anaesthetic-induced cardiac arrhythmia. MiRP1(T8A) does not seem to confer an increased risk of severe cardiac side-effects to carriers of this common polymorphism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14665560     DOI: 10.1093/bja/aeh026

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  8 in total

Review 1.  Modification of K+ channel-drug interactions by ancillary subunits.

Authors:  Glenna C L Bett; Randall L Rasmusson
Journal:  J Physiol       Date:  2007-12-20       Impact factor: 5.182

2.  Blockade of HERG cardiac K+ current by antifungal drug miconazole.

Authors:  Kan Kikuchi; Toshihisa Nagatomo; Haruhiko Abe; Kazunobu Kawakami; Henry J Duff; Jonathan C Makielski; Craig T January; Yasuhide Nakashima
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

Review 3.  [Long QT syndrome and anaesthesia].

Authors:  S Rasche; T Koch; M Hübler
Journal:  Anaesthesist       Date:  2006-03       Impact factor: 1.041

4.  Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy.

Authors:  Kazunobu Kawakami; Toshihisa Nagatomo; Haruhiko Abe; Kan Kikuchi; Hiroko Takemasa; Blake D Anson; Brian P Delisle; Craig T January; Yasuhide Nakashima
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

5.  Bupivacaine blocks N-type inactivating Kv channels in the open state: no allosteric effect on inactivation kinetics.

Authors:  Johanna Nilsson; Michael Madeja; Fredrik Elinder; Peter Arhem
Journal:  Biophys J       Date:  2008-09-12       Impact factor: 4.033

6.  [Perioperative treatment of patients with long QT syndrome].

Authors:  T Krönauer; P Friederich
Journal:  Anaesthesist       Date:  2015-08       Impact factor: 1.041

Review 7.  Interaction of local anesthetics with biomembranes consisting of phospholipids and cholesterol: mechanistic and clinical implications for anesthetic and cardiotoxic effects.

Authors:  Hironori Tsuchiya; Maki Mizogami
Journal:  Anesthesiol Res Pract       Date:  2013-09-23

8.  Differential association between HERG and KCNE1 or KCNE2.

Authors:  Sung Yon Um; Thomas V McDonald
Journal:  PLoS One       Date:  2007-09-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.